Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
19
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$6.16
Seasonality move
:
12.54%
Day range:
$6.16 - $6.16
52-week range:
$6.16 - $13.43
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.79x
P/B ratio:
1.17x
Volume:
--
Avg. volume:
137
1-year change:
-37.04%
Market cap:
$553.6M
Revenue:
$91M
EPS (TTM):
-$0.27
Analysts' Opinion
-
Consensus RatingNxera Pharma has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Nxera Pharma has an estimated downside of -- from its current price of $6.16.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $6.16.
Fair Value
-
According to the consensus of 0 analysts, Nxera Pharma has -- downside to fair value with a price target of -- per share.
SOLTF vs. S&P 500
-
Over the past 5 trading days, Nxera Pharma has underperformed the S&P 500 by -12.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nxera Pharma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nxera Pharma has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Nxera Pharma reported revenues of $62.4M.
Earnings Growth
-
Nxera Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Nxera Pharma reported earnings per share of $0.09.
Enterprise value:
665.8M
EV / Invested capital:
0.72x
Price / LTM sales:
2.79x
EV / EBIT:
--
EV / Revenue:
3.42x
PEG ratio (5yr expected):
--
EV / Free cash flow:
66.55x
Price / Operating cash flow:
54.27x
Enterprise value / EBITDA:
96.78x
Gross Profit (TTM):
$146.8M
Return On Assets:
-2.38%
Net Income Margin (TTM):
-12.61%
Return On Equity:
-5.58%
Return On Invested Capital:
-2.75%
Operating Margin:
8.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $189M | $88.1M | $194.8M | $23M | $62.4M | |
| Gross Profit | $180.5M | $77.3M | $146.8M | $15.2M | $48.9M | |
| Operating Income | $62.1M | -$28.7M | -$29.4M | -$26.5M | $5.4M | |
| EBITDA | $55.4M | -$4.7M | $6.9M | -$18.4M | $13.8M | |
| Diluted EPS | -$0.02 | -$0.29 | -$0.27 | -$0.41 | $0.09 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $377.3M | $462.9M | $440.2M | $390.3M | $419.1M | |
| Total Assets | $693.8M | $794.6M | $658.8M | $1B | $1.1B | |
| Current Liabilities | $21.2M | $33.7M | $21.2M | $117.6M | $104.7M | |
| Total Liabilities | $237.4M | $314.3M | $273.2M | $612.4M | $592.2M | |
| Total Equity | $456.4M | $480.4M | $385.6M | $387.9M | $474.5M | |
| Total Debt | $139.3M | $243.9M | $192.7M | $457.2M | $454.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $126M | $10.4M | $15.1M | -$9.1M | $12.2M | |
| Cash From Investing | -$1.4M | -$427.3M | -$17.7M | -$423M | -$1.6M | |
| Cash From Financing | -$35.3M | $271.6M | $35.5M | $274.9M | -$12.4M | |
| Free Cash Flow | $123.7M | $6M | $10M | -$11.1M | $10.3M | |
SOLTF
Sector
Market Cap
$553.6M
$46.1M
Price % of 52-Week High
45.85%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-37.04%
-30.52%
Beta (5-Year)
0.337
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$6.59
200-day SMA
Sell
Level
$9.15
Bollinger Bands (100)
Sell
Level
7.33 - 9.45
Chaikin Money Flow
Buy
Level
11.1K
20-day SMA
Sell
Level
$7.13
Relative Strength Index (RSI14)
Sell
Level
9.27
ADX Line
Sell
Level
47.48
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$7.51
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-39.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9687)
Sell
CA Score
(Annual)
Level (-0.7596)
Sell
Beneish M-Score
(Annual)
Level (-1.2854)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.411)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.
Stock Forecast FAQ
In the current month, SOLTF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SOLTF average analyst price target in the past 3 months is --.
-
Where Will Nxera Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nxera Pharma share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Nxera Pharma?
Analysts are divided on their view about Nxera Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nxera Pharma is a Sell and believe this share price will rise from its current level to --.
-
What Is Nxera Pharma's Price Target?
The price target for Nxera Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SOLTF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nxera Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SOLTF?
You can purchase shares of Nxera Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nxera Pharma shares.
-
What Is The Nxera Pharma Share Price Today?
Nxera Pharma was last trading at $6.16 per share. This represents the most recent stock quote for Nxera Pharma. Yesterday, Nxera Pharma closed at $6.16 per share.
-
How To Buy Nxera Pharma Stock Online?
In order to purchase Nxera Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
